PARADIGM-2314 (Completed)

A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure and reduced ejection fraction

Medicine: LCZ 696 vs enalapril
Population: Heart failure
Phase: III
Starting year: 2009
More information: ClinicalTrials.gov

Director of Study

dr. A. Mosterd (Cardioloog)
Amersfoort, Meander Medisch Centrum

Publications: PARADIGM-2314

Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart FailureCirculation - Abstract - Linssen, dr. G.C.M. - PARADIGM-2314 - Heart failure November 2019
Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF.J Am Coll Cardiol - Abstract - Mosterd, dr. A. - PARADIGM-2314 - Heart failure November 2015
A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure.Eur Heart J - Abstract - Mosterd, dr. A. - PARADIGM-2314 - Heart failure February 2015
A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure.Eur Heart J - Abstract - Mosterd, dr. A. - PARADIGM-2314 - Heart failure February 2015
Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure.Circulation - Abstract - Mosterd, dr. A. - PARADIGM-2314 - Heart failure January 2015
Discussant: PARADIGM Heart FailureESC 2014 - PARADIGM-2314 - Heart failure August 2014
Results of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)ESC 2014 - PARADIGM-2314 - Heart failure August 2014

Publications by WCN study

Publications WCN studies by WCN member